Literature DB >> 3709651

Dose-dependent pharmacokinetics of dexamethasone.

D Loew, O Schuster, E H Graul.   

Abstract

The dose dependency of the pharmacokinetics of dexamethasone and its influence on the endogenous secretion of cortisol has been studied in healthy females. The maximum plasma level occurred between 1.6 and 2.0 h after doses of 0.5-3.0 mg independent of the type of administration. AUC, distribution volume, plasma clearance and cmax did not increase in proportion to the dose but only by the factor of about 0.6-0.7 after the oral administration of 0.5-1.5 mg. Comparatively high values were reached after 3.0 mg i.m. This may be due to reduced bioavailability of the oral doses. Within the first 12 h after the administration of 0.5-3.0 mg, endogenous cortisol secretion was influenced independent of dose. However, the suppressive effect after 24 h was dose dependent and amounted to approximately 24% for 0.5 mg p.o., 62% for 1.5 mg p.o. and 90% for 3.0 mg i.m. In the case of administration every second day, the integral reduction within 24 h after the administration of 0.5 mg dexamethasone was 44 to 65% and for 1.5 mg between 59 and 62%.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709651     DOI: 10.1007/bf00614309

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Bioavailability of oral dexamethasone.

Authors:  D E Duggan; K C Yeh; N Matalia; C A Ditzler; F G McMahon
Journal:  Clin Pharmacol Ther       Date:  1975-08       Impact factor: 6.875

2.  Binding of corticosteroids by plasma proteins. V. Corticosteroid-binding globulin activity in normal human beings and in certain disease states.

Authors:  W H DAUGHADAY
Journal:  AMA Arch Intern Med       Date:  1958-02

3.  A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man.

Authors:  P L Ballard; J P Carter; B S Graham; J D Baxter
Journal:  J Clin Endocrinol Metab       Date:  1975-08       Impact factor: 5.958

4.  Tissue effects of glucocorticoids.

Authors:  J D Baxter; P H Forsham
Journal:  Am J Med       Date:  1972-11       Impact factor: 4.965

5.  Dose-dependent prednisolone kinetics.

Authors:  A Tanner; F Bochner; J Caffin; J Halliday; L Powell
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

6.  Absorption and metabolism of orally administered beclomethsone dipropionate.

Authors:  L E Martin; R J Tanner; T J Clark; G M Cochrane
Journal:  Clin Pharmacol Ther       Date:  1974-03       Impact factor: 6.875

7.  Effect of dose size on the pharmacokinetics of intravenous hydrocortisone during endogenous hydrocortisone suppression.

Authors:  R D Toothaker; P G Welling
Journal:  J Pharmacokinet Biopharm       Date:  1982-04

8.  Plasma protein binding of triamcinolone-H3 and hydrocortisone-4-C14.

Authors:  J R FLORINI; D A BUYSKE
Journal:  J Biol Chem       Date:  1961-01       Impact factor: 5.157

9.  Plasma binding of betamethasone-3H, dexamethasone-3H, and cortisol-14C--a comparative study.

Authors:  E A Peets; M Staub; S Symchowicz
Journal:  Biochem Pharmacol       Date:  1969-07       Impact factor: 5.858

10.  A comparison of the bioavailability and potency of dexamethasone phosphate and sulphate in man.

Authors:  S Miyabo; T Nakamura; S Kuwazima; S Kishida
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more
  21 in total

1.  Cortisol suppression and hearing thresholds in tinnitus after low-dose dexamethasone challenge.

Authors:  Veerle L Simoens; Sylvie Hébert
Journal:  BMC Ear Nose Throat Disord       Date:  2012-03-26

2.  Pharmacokinetic and pharmacodynamic interactions between dehydroepiandrosterone and prednisolone in the rat.

Authors:  G M Meno-Tetang; Y Y Hon; S Van Wart; W J Jusko
Journal:  Drug Metabol Drug Interact       Date:  1999

3.  The pharmacokinetics of low-dose dexamethasone in congenital adrenal hyperplasia.

Authors:  M C Young; N Cook; G F Read; I A Hughes
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia.

Authors:  Simone M C Spoorenberg; Vera H M Deneer; Jan C Grutters; Astrid E Pulles; G P Paul Voorn; Ger T Rijkers; Willem Jan W Bos; Ewoudt M W van de Garde
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

5.  In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery.

Authors:  C S Leopold; D R Friend
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

6.  Injectable dexamethasone sodium phosphate administered orally? A pharmacokinetic analysis of a common emergency department practice.

Authors:  Alexander Toledo; Christopher S Amato; Nigel Clarke; Richard E Reitz; David Salo
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

7.  The effect of glucocorticoids on tendon cell viability in human tendon explants.

Authors:  Margaret Wan Nar Wong; Wai Ting Lui; Sai Chuen Fu; Kwong Man Lee
Journal:  Acta Orthop       Date:  2009-06       Impact factor: 3.717

Review 8.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

9.  Methylprednisolone pharmacokinetics after intravenous and oral administration.

Authors:  S M Al-Habet; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

10.  Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.

Authors:  Brendan Johnson; Laurel Adams; Emily Lu; Ke Zhang; Peter Lebowitz; Christian Lates; Robert Blum
Journal:  Support Care Cancer       Date:  2009-02-10       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.